Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
13.02
-0.63 (-4.62%)
At close: Jul 6, 2026, 4:00 PM EDT
13.01
-0.01 (-0.08%)
After-hours: Jul 6, 2026, 4:00 PM EDT
Atrium Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Accelerated approval pathway for FSHD is now open, with Delvotax showing consistent improvements in muscle function, mobility, and quality of life in the Fortitude study. The CDUX biomarker is validated as a surrogate endpoint, and both the pivotal and confirmatory phase 3 studies are underway, targeting global enrollment and efficient regulatory submissions.